Inhibitory effect of acetylsalicylic acid on matrix metalloproteinase - 2 Activity in human endothelial cells exposed to high glucose

Journal of Cellular and Molecular Medicine

Volumn 9, Issue 4, 2005, Pages 953-960

  Nicolae, Manuela ^a   Tircol, Magdalena ^a   Alexandru, Dorin ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

Acetylsalicylic acid; Angiogenesis; Diabetes; Endothelial cell; MMP 2

Indexed keywords

EID: 30944432778     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2005.tb00391.x     Document Type: Article

References (22)

1. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res. 2003; 92: 827-39.
2. Galis ZS. Physiological and pathological remodeling of vascular matrix by matrix metalloproteinases. Acad Med Kinki Univ. 1999; 24: 45-53.
3. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements M, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994; 370: 555-7.
4. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA. 1996; 93: 7069-74.
5. Lijnen HR, Ugwu F, Bini A, Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998; 37: 4699-702.
6. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol. 2001; 33: 960-70.
7. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17: 463-516.
8. Jones L, Ghaneh P, Humphreys M, Neoptolemos JP. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann NY Acad Sci. 1999; 880: 288-307.
9. Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Gearing AJ, Huxley P, Laber D, McCourt M, Whittaker M, Wood LM, Wright A. Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 1999; 878: 228-35.
10. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000; 6: 149-56.
11. Svab I, Alexandru D, Vitos G, Flonta ML. Binding affinities for sulfonamide inhibitors with matrix metalloproteinase-2 using a linear response method. J Cell Mol Med.. 2004; 8: 551-62.
12. Pan MR, Chuang LY, Hung WC. Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Letters 2001; 508: 365-8.
13. Jiang MC, Liao CF, Lee PH. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun. 2001; 282: 671-7.
14. Pan MR, Hung WC. Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem. 2002; 277: 32775-80.
15. Kama E, Palka JA. Inhibitory effect of acetylsalicylic acid on metalloproteinase activity in human lung adenocarcinoma at different stages of differentiation. Eur J Pharmacol. 2002; 443: 1-6.
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-54.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55-63.
18. Death AK, Fisher EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003; 16: 263-9.
19. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res. 2001; 88: 1291-8.
20. Sulochana KN, Ramakrishnan S, Rajesh M, Coral K, Badrinath SS. Diabetic retinopathy: Molecular mechanisms, present regime of treatment and future perspectives. Curr Sci. 2001; 80: 133-42.
21. Guoping L, Yang T, Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun. 2002; 299: 886-90.
22. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adamis AP. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-α suppression. FASEB J. 2002; 16: 438-40.